Mesoblast Stock Today
| MESO Stock | USD 14.74 -0.06 -0.41% |
Performance 0High 0 · Weak | Odds Of Distress HighLow 11 · Low |
Mesoblast holds a current price of $14.74 as of May 8, 2026, delivering a 0.41% decrease on the day. Forward-looking probability metrics estimate that Mesoblast carries 11% odds of experiencing financial distress. Over the last 90 trading days, it has delivered negative risk-adjusted returns. The performance scores are based on the time frame from February 7, 2026 to May 8, 2026. Learn more.
IPO Date 13th of November 2015 | Asset Type Stock | Category Healthcare | Classification Health Care |
Follow Valuation Options Odds of Bankruptcy
Mesoblast (MESO) is listed on NASDAQ Exchange in USA. Mesoblast operates within the Biotechnology segment. Market capitalization for Mesoblast is about $1.91 billion, leaving the company classified as mid-cap across biotechnology companies. To frame that market cap reading, note enterprise value near $1.95 billion and about 129.28 million shares outstanding. Mesoblast has 3.05 million shares sold short (10.39 days to cover). The gap between operating margin (-55.16%) and net margin (-144.33%) suggests significant non-operating costs such as interest or taxes. Mesoblast is a research-driven pharmaceutical developer where revenue is driven by pipeline advancement, approvals, and patent-protected revenue. MESO has return on total asset (ROA) of -6.16% a negative efficiency signal. Negative, reflecting an operating or net loss. Mesoblast also reports a return on stockholder's equity (ROE) of -18.22%, suggesting that retained earnings are insufficient to offset equity losses. Mesoblast financial stability analysis Ownership Allocation Mesoblast records a 5.05% of its outstanding shares held by insiders and 3.54% owned by institutional investors.
Check Mesoblast Ownership Details Check how we calculate scores
Market Sentiment and Price Pattern for Mesoblast
Average sentiment trends provide additional analytical context alongside traditional valuation metrics. Behavioral sentiment models show that Mesoblast currently carries a strongly positive sentiment profile, based on evaluation of limited recent coverage and information signals as of 2026-05-01.
Open Interest Against 2026-07-17 Mesoblast Option Contracts
This chain summary highlights Mesoblast listed contracts for July 17, 2026. At this expiration, the listing mix is 17 calls and 15 puts (32 total). At a glance, metrics point to implied volatility near 1.13 and put/call open-interest ratio around 0.16. Strike-level open interest is available in the full chain. View Options.Open interest in Mesoblast options reflects the number of outstanding contracts. Contract activity trends can provide insight into derivatives positioning.
ESG SustainabilityFor Mesoblast, recent data highlights an ESG Environmental Score of 62.20, an ESG Governance Score of 64.57, and an ESG Social Score of 66.77. Mesoblast's ESG alignment falls in the upper-middle tier within Biotechnology. Governance oversight and environmental disclosures contribute to broader assessments of operational consistency.
Environmental | Governance | Social |
Stock Notable Updates
| Legal Name | Mesoblast Ltd |
| Scientific Advisor to the CEO | Paul BSc |
| Chairman | Silviu FACP |
| Thematic Idea | Cancer Fighters (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare, (View all Sectors) |
For Mesoblast, recent data highlights a Gross Profit Margin of 85.0%, an Operating Margin of -55.2%, and a Return On Assets of -12.0%. Mesoblast demonstrates pressured financial positioning across liquidity and leverage indicators. The earnings picture reflects near-term margin compression relative to deployed assets.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.05 | 0.03 |
|
| |||||
| Total Current Liabilities | $123.92 million | $118.02 million |
|
| |||||
| Non Current Liabilities Total | $116.38 million | $76.15 million |
|
| |||||
| Total Assets | $596.41 million | $902.39 million |
|
| |||||
| Total Current Assets | $121.63 million | $235 million |
|
|
Current Assets
For Mesoblast, recent data highlights $0.46 in Intangibles To Total Assets, $596.4 million in Total Assets, and a Return On Assets of -12.0%. a Return On Tangible Assets of -58.0% round out the key financial metrics view for Mesoblast.
Earnings per Share Projection vs Actual
Mesoblast's forward EPS estimates provide a structured view of expected profitability based on current analyst coverage. Mesoblast generates 17.2 million in revenue, establishing the scale over which earnings per share are distributed.
For Mesoblast, estimated EPS values represent current analyst expectations and remain subject to revision. EPS TTM is backward-looking and may diverge from future outcomes.
Top Institutional Holders
Institutional Holdings in Mesoblast refers to the portion of shares owned by major financial entities. These holders often acquire large positions in Mesoblast and influence management through their ownership.| Instituion | Recorded On | Shares | |
| Lpl Financial Corp | 2025-12-31 | 48.7 K | |
| Rialto Wealth Management, Llc | 2025-12-31 | 46.5 K | |
| Point72 Asset Management, L.p. | 2025-12-31 | 38.2 K | |
| Geode Capital Management, Llc | 2025-12-31 | 30.7 K | |
| Quadrature Capital Limited | 2025-12-31 | 26.6 K | |
| Citigroup Inc | 2025-12-31 | 26.4 K |
Mesoblast Historical Income Statement
Income Tax Expense stood at $297,000 as of December 31, 2025. Meanwhile, Selling And Marketing Expenses is near current levels at $14.49 million, while Selling General Administrative is staying broadly flat near $26.69 million. View More FundamentalsMesoblast Against Markets
| NYA | 0.30 | ||||
| MESO | 0.41 |
| Competition | Compare Correlations |
Stock Overview, Methodology & Data Sources
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Headquarters are in 55 Collins Street, Melbourne, VIC, Australia, 3000. Latest reported figures include market cap 1.91 billion, P/B 3.56, P/S 29.26. Mesoblast operates in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Fundamentals lead the analysis, with market-implied risk context alongside. Certain defensive traits may reduce sensitivity to broader macroeconomic fluctuations.
Methodology
Unless otherwise specified, financial data for Mesoblast is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Mesoblast (USA Stocks:MESO) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: Inputs rely on public filings and market reference sources and institutional disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Publication cadence can introduce timing differences. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Mesoblast may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board
Mesoblast Corporate Management
| Fiona See | Senior VP & Head of Translational Research | Profile | |
| Geraldine BSc | Head of Regulatory Affairs & Quality Management | Profile | |
| Peter BSc | General Counsel & Corporate Executive | Profile | |
| Justin BS | Head of Manufacturing | Profile | |
| Daniel BSc | Head of Special Projects | Profile | |
| Roger BA | Head Disorders | Profile | |
| BSc LLB | Gen Exec | Profile |